Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Income towards Parent Company: 2014-2024

Historic Income towards Parent Company for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$77.4 million.

  • Cartesian Therapeutics' Income towards Parent Company fell 30.10% to -$19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.7 million, marking a year-over-year increase of 59.92%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • Cartesian Therapeutics' Income towards Parent Company amounted to -$77.4 million in FY2024, which was up 64.76% from -$219.7 million recorded in FY2023.
  • Over the past 5 years, Cartesian Therapeutics' Income towards Parent Company peaked at $35.4 million during FY2022, and registered a low of -$219.7 million during FY2023.
  • Moreover, its 3-year median value for Income towards Parent Company was -$77.4 million (2024), whereas its average is -$87.3 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Income towards Parent Company surged by 237.73% in 2022, and later crashed by 721.02% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Income towards Parent Company stood at -$68.9 million in 2020, then soared by 62.71% to -$25.7 million in 2021, then soared by 237.73% to $35.4 million in 2022, then plummeted by 721.02% to -$219.7 million in 2023, then soared by 64.76% to -$77.4 million in 2024.